Jun 14, 2021 7:01pm Ada Health’s smartphone app, which uses artificial intelligence to analyze a user’s self-reported symptoms and suggest a list of potential causes, has already attracted plenty of attention from Big Pharma, including a Bayer-led series B and a recently expanded collaboration with Novartis. (Ada Health)
Typically, when pharmaceutical companies turn to medtech developers for support, they’re in the market to boost their drug discovery and development capabilities with the help of a shiny new artificial intelligence tool or to deploy a smartphone app to monitor the effects of an already available drug.
But the software developer currently making big waves across Big Pharma is focused on intervening much earlier in the treatment process at the very beginning, in fact, before treatment has even begun.
Kajeet Director of Strategy Dominic Marcellino to Deliver Partner Keynote at Fierce MedTech Innovation Week on April 26, 2021
Share Article
Marcellino will join medical industry experts for a virtual discussion on how the telehealth revolution is transforming healthcare MCLEAN, Va. (PRWEB) April 20, 2021 WHAT
The rise of IoT and connected devices that facilitate data streaming are helping healthcare providers trailblaze new care delivery models outside of traditional clinical settings, such as remote patient monitoring and digital diagnostic - even robotic surgery. As new and emerging technologies continue to enhance the delivery of safe and effective care, ensuring secure and reliable connectivity is critical to lasting adoption and future medtech innovations.
Caption Health Announces Steve Cashman as New President and CEO yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Apr 5, 2021 3:30pm Inscripta’s latest funding round will support the development and distribution of its Onyx benchtop platform, which uses CRISPR gene editing technology for fully automated genomic engineering. (AstraZeneca)
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses.
The genomic engineering company, a member of Fierce Medtech’s 2019 Fierce 15, recently closed a series E funding round totaling $150 million. The investment was led by Fidelity Management and Research Company and funds and accounts managed by T. Rowe Price Associates.
Upon the close of a $125 million series D round in December 2019, Inscripta calculated its total amount of funds raised since its 2015 founding at $259.5 million. With the latest influx of funds and an extension of the series D in November 2020, that total now clocks in at well over $450 million.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Babson Diagnostics Named Fierce MedTech “Fierce 15” Company
March 9, 2021 GMT
AUSTIN, Texas (BUSINESS WIRE) Mar 9, 2021
Babson Diagnostics (Babson), a transformative medical technology company improving customer access to diagnostic blood testing, was named one of Fierce Medtech’s elite “Fierce 15.” The honor recognizes Babson as one of the most promising private companies in the global healthcare industry. In the year of COVID-19, Fierce Medtech, a leading daily digital news publication, examined how med tech companies are addressing the most pressing public health challenges.
ADVERTISEMENT
The conventional diagnostic blood testing experience has not changed notably since it was created 70 years ago. Babson Diagnostics is the first company to present a true alternative to venipuncture, with novel technology designed to use small fingertip samples less than one-tenth the vol